**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 52691

**Manuscript Type:** ORIGINAL ARTICLE

***Prospective Study***

**Technetium-99m-labeled macroaggregated albumin lung perfusion scan for diagnosis of hepatopulmonary syndrome: A prospective study comparing brain uptake and whole-body uptake**

Zhao H *et al*. Brain uptake *vs* whole-body uptake derived from MAA scan for diagnosing HPS

He Zhao, Jiaywei Tsauo, Xiao-Wu Zhang, Huai-Yuan Ma, Ning-Na Weng, Gong-Shun Tang, Xiao Li

**He Zhao, Jiaywei Tsauo, Xiao-Wu Zhang, Xiao Li,** Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

**He Zhao, Huai-Yuan Ma, Ning-Na Weng, Xiao Li,** Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

**Gong-Shun Tang,** Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

**Author contributions:** Zhao H, Tsauo J, Weng NN, Zhang XW and Tang GS performed the research; Ma HY analyzed the data; Li X and Tsauo J designed and coordinated the research; Zhao H wrote the paper.

**Supported by** National Key R and D Program of China, No. 2017YFC0107800; CAMS Initiative for Innovative Medicine, No. 2016-12M-2-004.

**Corresponding author: Xiao Li, MD, PhD, Doctor, Postdoc, Professor,** Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. simonlixiao@gmail.com

**Received:** November 14, 2019

**Revised:** January 6, 2020

**Accepted:** January 19, 2020

**Published online:** March 14, 2020

Abstract

BACKGROUND

Hepatopulmonary syndrome (HPS) is an arterial oxygenation defect induced by intrapulmonary vascular dilatation (IPVD) in the setting of liver disease and/or portal hypertension. This syndrome occurs most often in cirrhotic patients (4%–32%) and has been shown to be detrimental to functional status, quality of life, and survival. The diagnosis of HPS in the setting of liver disease and/or portal hypertension requires the demonstration of IPVD (*i.e.* diffuse or localized abnormally dilated pulmonary capillaries and pulmonary and pleural arteriovenous communications) and arterial oxygenation defects, preferably by contrast-enhanced echocardiography and measurement of the alveolar-arterial oxygen gradient, respectively.

AIM

To compare brain and whole-body uptake of technetium for diagnosing HPS.

Methods

Sixty-nine patients with chronic liver disease and/or portal hypertension were prospectively included. Brain uptake and whole-body uptake were calculated using the geometric mean of technetium counts in the brain and lungs and in the entire body and lungs, respectively.

Results

Thirty-two (46%) patients had IPVD as detected by contrast-enhanced echocardiography. The demographics and clinical characteristics of the patients with and without IPVD were not significantly different with the exception of the creatinine level (0.71 ± 0.18 mg/dL *vs* 0.83 ± 0.23 mg/dL; *P* = 0.041), alveolar-arterial oxygen gradient (23.2 ± 13.3 mmHg *vs* 16.4 ± 14.1 mmHg; *P* = 0.043), and arterial partial pressure of oxygen (81.0 ± 12.1 mmHg *vs* 90.1 ± 12.8 mmHg; *P* = 0.004). Whole-body uptake was significantly higher in patients with IPVD than in patients without IPVD (48.0% ± 6.1% *vs* 40.1% ± 8.1%; *P* = 0.001). The area under the curve of whole-body uptake for detecting IPVD was significantly higher than that of brain uptake (0.75 *vs* 0.54; *P* = 0.025). The optimal cut-off values of brain uptake and whole-body uptake for detecting IPVD were 5.7% and 42.5%, respectively, based on Youden’s index. The sensitivity, specificity, and accuracy of brain uptake > 5.7% and whole-body uptake > 42.5% for detecting IPVD were 23%, 89%, and 59% and 100%, 52%, and 74%, respectively.

Conclusion

Whole-body uptake is superior to brain uptake for diagnosing HPS.

**Key words:** Portal hypertension; Intrapulmonary vascular dilations; Radionuclide imaging; Technetium-99m-labeled macroaggregated albumin lung perfusion scan; Diagnostic tests; Sensitivity and specificity

Zhao H, Tsauo J, Zhang X, Ma H, Weng N, Tang G, Li X. Technetium-99m-labeled macroaggregated albumin lung perfusion scan for diagnosis of hepatopulmonary syndrome: A prospective study comparing brain uptake and whole-body uptake. *World J Gastroenterol* 2020; 26(10): 1088-1097

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i10/1088.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i10.1088

**Core tip:** Hepatopulmonary syndrome is a common complication of liver disease that impairs the lungs’ ability to oxygenate blood, leading to debilitating symptoms, such as shortness of breath. Intrapulmonary vascular dilations, a hallmark of hepatopulmonary syndrome, can be detected using technetium-99m-labeled macroaggregated albumin lung perfusion scan; however, of the two most commonly used methods of result interpretation (*i.e.* brain uptake and whole-body uptake), it is unclear which is more accurate. In this study of 69 patients with liver cirrhosis, we found that whole-body uptake is more accurate than brain uptake for detecting intrapulmonary vascular dilations.

**INTRODUCTION**

Hepatopulmonary syndrome (HPS) is an arterial oxygenation defect induced by intrapulmonary vascular dilatation (IPVD) in the setting of liver disease and/or portal hypertension[1,2]. This syndrome occurs most often in cirrhotic patients (4%–32%) and has been shown to be detrimental to functional status, quality of life, and survival[3,4]. The diagnosis of HPS in the setting of liver disease and/or portal hypertension requires the demonstration of IPVD (*i.e.* diffuse or localized abnormally dilated pulmonary capillaries and pulmonary and pleural arteriovenous communications) and arterial oxygenation defects, preferably by contrast-enhanced echocardiography (CEE) and measurement of the alveolar-arterial oxygen gradient (AaO2), respectively[1]. Although a technetium-99m (Tc-99m)-labeled macroaggregated albumin (MAA) lung perfusion scan is not the preferred method for detecting IPVD due to its low sensitivity (20%–96%) compared to CEE, it is an important complimentary tool to CEE for diagnosing HPS[1,5-8]. An MAA lung perfusion scan can determine the degree of IPVD *via* the shunt fraction, which can be used to assess the contribution of HPS to arterial oxygenation defects in patients with coexisting pulmonary disease and to determine the prognosis of HPS patients undergoing liver transplantation[9,10]. In addition, CEE is unfeasible in 5%–7% of patients due to inadequate echocardiographic window[3,11,12].

Both brain uptake and whole-body uptake have been used to determine the shunt fraction[8,13,14]. In the former, the shunt fraction is calculated based on the technetium uptake in the brain, which is assumed to receive 13% of the cardiac output, and the lungs, whereas the latter is based on the technetium uptake in the whole body and the lungs[7]. Although whole-body uptake has been more widely used in general, brain uptake is considered the standard technique for diagnosing HPS[1,14]. This is mainly because whole-body scans require a longer acquisition time than local scans; therefore, they may be associated with a theoretical risk of overestimating the shunt fraction due to the breakdown of MAA particles over time. However, the assumption that the brain receives 13% of the cardiac output may not be applicable to patients with liver disease and/or portal hypertension because this value is based on healthy subjects[15]. In cirrhotic patients, the brain may receive a lower percentage of the cardiac output than in healthy subjects due to cerebral vasoconstriction[16,17]. Therefore, brain uptake may be associated with a theoretical risk of underestimating the shunt fraction in cirrhotic patients. To the best of our knowledge, brain uptake and whole-body uptake have not been compared for the diagnosis of HPS. This question is of interest because its answer may allow for more accurate diagnosis of HPS in patients unfeasible to CEE and more accurate quantification of the degree of IPVD. The purpose of this study was to compare brain uptake and whole-body uptake for diagnosing HPS.

**MATERIALS AND METHODS**

*Study design*

This prospective study was approved by the Institutional Review Board of West China Hospital (Identifier, 2014-234). All patients provided written informed consent. From December 2014 to October 2015, all patients with chronic liver disease and/or portal hypertension admitted to our institution for an elective interventional radiologic procedure (*e.g.*, transjugular intrahepatic portosystemic shunt or balloon angioplasty of the obstructed hepatic veins and/or inferior vena cava) were eligible for inclusion. Chronic liver disease and portal hypertension were diagnosed by clinical, laboratory, imaging, and, when necessary, histologic findings. The exclusion criteria were age < 18 years, forced expiratory volume in one second (FEV1) < 70% predicted, forced vital capacity (FVC) < 70% predicted, FEV1/FVC < 70% predicted, pulmonary artery systolic pressure > 35 mmHg, QT interval > 50% of the RR interval, intracardiac shunting, active infection, pregnancy, or a previous transjugular intrahepatic or surgical portosystemic shunt.

***IPVD detection and HPS diagnosis***

CEE was used to detect IPVD. The technique used to perform CEE has been described in detail elsewhere[18]. Briefly, agitated saline produced by flushing 9.5 mL of saline with 0.5 mL of room air between two 10 mL Luer-Lock syringes was intravenously injected, and transthoracic two-dimensional echocardiography in the parasternal four-chamber view was used to detect the appearance of microbubbles. The result was regarded as positive if any microbubbles appeared in the left heart chambers three to six heartbeats after their initial appearance in the right heart chambers[1]. The appearance of any microbubbles in the left heart chambers less than three heartbeats after their initial appearance in the right heart chambers indicated the presence of an intracardiac shunt. The result was regarded as negative if no microbubbles appeared in the left heart chambers after three injections. All CEE results were interpreted by consensus of two blinded echocardiologists with more than 10 years of experience. The diagnosis of HPS was established by a positive CEE result and an elevated AaO2 [*i.e.* ≥ 15 mmHg (≥ 20 mmHg in patients aged ≥ 65 years)][19]. The severity of HPS was classified as very severe [arterial partial pressure of oxygen (PaO2) < 50 mmHg], severe (PaO2 50–59 mmHg), moderate (PaO2 60–79 mmHg), or mild (PaO2 ≥ 80 mmHg)[1].

*MAA lung perfusion scan procedure*

The MAA kit used in this study was purchased from by Jiangsu Institute of Nuclear Medicine (Jiangsu, China). A total of 10–30 mCi of Tc-99m in 5 mL of saline was injected into a 10-mL bottle containing 2 mg of aggregated albumin (particles size between 10–90 μm) and 0.15 mg stannous chloride. The bottle was rocked for 1 min and, occasionally, the radiochemical purity of the Tc-99m MAA was determined with paper chromatography (purity normally > 99%) 5 min later. With the patient in an upright position, 2 mCi of Tc-99m MAA particles was injected through an intravenous line placed in the upper extremity. Subsequently, local images (*i.e.* left and right lateral head and anterior and posterior chest) and whole-body images (*i.e.* anterior and posterior whole-body) were acquired sequentially using a single photon emission computed tomography system (Precedence; Philips Healthcare, Cleveland, OH, United States) immediately after injection of MAA particles. In all patients, the order of acquisition of images (*i.e.* local images followed by whole-body images or vice versa) was decided using computer-generated random numbers. The acquisition parameters were as follows: 64 × 64 matrix and 2 min of acquisition time per local image or 15–25 cm/min per whole-body image. Regions of interest were manually drawn using postprocessing software (Jetstream Workspace, Philips, the Netherlands) by consensus of two blinded experienced nuclear radiologists. Brain uptake was calculated using the geometric mean of the technetium (GMT) counts in the brain, which is assumed to receive 13% of the cardiac output, and the lungs as follows: (GMTbrain / 0.13) / (GMTbrain / 0.13 + GMTlungs). In contrast, the whole-body uptake was calculated using the GMT counts in the whole-body and the lungs as follows: (1 - GMTlungs / GMTwhole-body).

*Statistical analysis*

Variables were compared using Student’s *t*-test, the Mann-Whitney *U* test, the **2 test, or Fisher’s exact test as appropriate. Pearson’s correlation or Spearman's rank correlation test were used to investigate relationships between the variables. Multivariable logistic regression with backward elimination was performed to identify variables that were independently associated with IPVD. Receiver operating characteristic curve analysis was conducted to evaluate the accuracy of brain uptake and whole-body uptake for detecting IPVD. A two-sided *P* value < 0.05 was considered to indicate a significant difference. All statistical analyses were conducted using MedCalc (version 15.2.2; MedCalc, Ostend, Belgium) or SPSS (version 21.0; SPSS, Armonk, NY, United States) statistical software.

**RESULTS**

A total of 81 patients were considered eligible for inclusion in this study. Twelve patients were excluded: Five due to an inadequate echocardiographic window, four due to intracardiac shunt, and three due to a previous transjugular intrahepatic portosystemic shunt. The remaining 69 patients were included (Figure 1). Of these patients, 32 (46%) had a positive CEE result and were therefore considered to have IPVD. The demographics and clinical characteristics of the patients with and without IPVD were not significantly different, with the exception of the creatinine level (0.71 ± 0.18 mg/dL *vs* 0.83 ± 0.23 mg/dL; *P* = 0.041), AaO2 (23.2 ± 13.3 mmHg *vs* 16.4 ± 14.1 mmHg; *P* = 0.043), and PaO2 (81.0 ± 12.1 mmHg *vs* 90.1 ± 12.8 mmHg; *P* = 0.004) (Table 1). Among the 32 patients with IPVD, 26 (81%) were considered to have HPS, as they had an elevated AaO2.The remaining six (19%) patients were considered to have subclinical HPS. Of the 26 patients with HPS, one (4%) had very severe HPS, 11 (42%) had moderate HPS, and 14 (54%) had mild HPS.

Thirty-three (48%) patients underwent acquisition of local images followed by whole-body images, whereas 36 (52%) underwent acquisition of whole-body images followed by local images. The demographics and clinical characteristics of the patients who underwent acquisition of local images followed by whole-body images were not significantly different from those of patients who underwent acquisition of whole-body images followed by local images (Table 2). The results of the MAA lung perfusion scan are presented in Table 1. No thyroid uptake was noted in any patient. Brain uptake was not significantly different between patients with and those without IPVD (5.3% ± 6.0% *vs* 3.6% ± 1.8%; *P* = 0.245) (Figure 2A). Conversely, whole-body uptake was significantly higher in patients with than in patients without IPVD (48.0% ± 6.1% *vs* 40.1% ± 8.1%; *P* = 0.001) (Figure 2B). Among the variables that were significantly different between patients with and those without IPVD, PaO2 and AaO2 were significantly correlated with one another (*P* < 0.001). Multivariable logistic regression showed that whole-body uptake was the only variable independently associated with IPVD [odds ratio, 1.29 (95% confidence interval (CI): 1.07–1.55); *P* = 0.008] (Table 3). The Hosmer-Lemeshow goodness-of-fit test showed that the logistic regression model used to identify variables independently associated with IPVD was well fit for the data (*P* = 0.551).

The area under the curve of whole-body uptake for detecting IPVD was significantly greater than that of brain uptake [0.75 (95%CI: 0.60–0.86) *vs* 0.54 (95%CI: 0.38–0.69); *P* = 0.025] (Figure 3). The optimal cut-off values of brain and whole-body uptake for detecting IPVD were 5.7% and 42.5%, respectively, based on Youden’s index. The sensitivity, specificity, and accuracy of CEE for detecting IPVD were 100%, 86%, and 91%, respectively (Table 4). Comparatively, the sensitivity, specificity, and accuracy of brain uptake > 5.7% and > 6% for detecting IPVD were only 23%, 89%, and 59% and 19%, 92%, and 59%, respectively. In contrast, the sensitivity, specificity, and accuracy of whole-body uptake > 42.5% for detecting IPVD were 100%, 52%, and 74%, respectively.

**DISCUSSION**

Brain uptake is calculated based on the assumption that the brain receives 13% of the cardiac output[7]. However, this assumption was derived from healthy subjects; therefore, it may not be applicable to patients with liver disease and/or portal hypertension. In fact, cirrhotic patients present a widespread reduction in intracranial blood flow, particularly in patients with ascites and more advanced cirrhosis[16]. In addition, brain uptake may also be affected by medications that affect cerebral circulation, such as propanol, vasopressin, and terlipressin[20,21]. Another concern with brain uptake is that the cut-off value of 6% was derived from only eight healthy subjects[6,17,22]. Despite these drawbacks, brain uptake is considered the standard technique for diagnosing HPS[1]. In contrast, as a more widely used technique in general, whole-body uptake is seldom used for diagnosing HPS, mainly because of the theoretical risk of overestimating the shunt fraction due to breakdown of MAA particles during whole-body scans, which require longer acquisition times than local scans. However, in this study, the order of acquisition of images did not significantly affect whole-body uptake and brain uptake, suggesting that the alterations in the shunt fraction caused by breakdown of MAA particles during these scans may be negligible.

In this study, we found: (1) Whole-body uptake was significantly greater in patients with than in patients without IPVD, whereas brain uptake was not significantly different between patients with and those without IPVD; (2) Whole-body uptake was the only independent predictor associated with the presence of IPVD; (3) The area under the curve of whole-body uptake for detecting IPVD was significantly higher than that of brain uptake; and (4) The sensitivity of whole-body uptake > 42.5% for detecting IPVD was 100%, whereas it was only 19% for brain uptake > 6%. Collectively, these results suggest that whole-body uptake is superior to brain uptake for diagnosing HPS. Underestimation of the shunt fraction due to inaccurate estimation of the distribution of the cardiac output to the brain may explain these results. In contrast, the suboptimal cut-off value (6%) was unlikely to be the reason for these results because the optimal cut-off value (5.7%) was comparable and produced similar results. It should be noted that the sensitivity of brain uptake in this study (19%) was lower than values reported in previous studies (20%–96%), most likely due to the high percentage of patients with mild or moderate HPS (96%), as the sensitivity of brain uptake is much lower in these patients than in patients with severe or very severe HPS[6-8,23].

Although whole-body uptake was more accurate than brain uptake for detecting IPVD, it remains to be less accurate than CEE, which suggests that CEE should remain the preferred method for diagnosing HPS. It should be noted, however, that MAA is an important complimentary tool to CEE in detecting HPS. This is because in approximately 5%–7% of patients, a conclusive result of IPVD cannot be obtained with CEE owing to inadequate echocardiographic windows[3,11,12]. Although transesophageal contrast-enhanced echocardiography could be an alternative in patients with poor image quality using CEE, it is more invasive than MAA lung perfusion scan[11]. In addition, CEE does not allow for quantifying the degree of IPVD, which is especially useful to estimate the degree of hypoxemia due to intrapulmonary shunting in patients with coexistent intrinsic cardiopulmonary disease and HPS. Therefore, in patients who were indicated for MAA lung perfusion scan to detect IPVD, whole-body uptake should be the preferred method over brain uptake, because it allows for more accurate diagnosis of HPS.

This study has several important limitations. First, the vast majority of the patients had only mild or moderate HPS; therefore, our results may not be applicable to patients with severe or very severe HPS. However, it should be noted that it is much more difficult to detect IPVD in patients with mild or moderate HPS than in patients with severe or very severe HPS[6,23]. Second, patients with different underlying liver diseases were included. Third, the order of acquisition of images was different between the two groups of patients, although our results did not show any statistically significant difference in uptake between the two groups.

In conclusion, whole-body uptake is superior to brain uptake for diagnosing HPS; therefore, it should be considered as the standard technique for calculating the shunt fraction. However, it should remain a complementary tool to CEE for diagnosing HPS due to its relatively lower sensitivity.

**ARTICLE HIGHLIGHTS**

***Research background***

Hepatopulmonary syndrome (HPS) is a common complication of liver disease that impairs the lungs’ ability to oxygenate blood, leading to debilitating symptoms, such as shortness of breath. Intrapulmonary vascular dilations (IPVD), a hallmark of HPS, can be detected using technetium-99m-labeled macroaggregated albumin lung perfusion scan.

***Research motivation***

Of the two most commonly used methods of result interpretation (*i.e.* brain uptake and whole-body uptake) for macroaggregated albumin lung perfusion scan, it is unclear which is more accurate for detecting IPVD and diagnosing HPS.

***Research objectives***

This study aimed to compare brain and whole-body uptake of technetium for diagnosing HPS and establish the standard technique for calculating the shunt fraction for the future research.

***Research methods***

Sixty-nine patients with chronic liver disease and/or portal hypertension were prospectively included. Brain uptake and whole-body uptake were calculated using the geometric mean of technetium counts in the brain and lungs and in the entire body and lungs, respectively.

***Research results***

Thirty-two (46%) patients had IPVD as detected by contrast-enhanced echocardiography. The area under the curve of whole-body uptake for detecting IPVD was significantly higher than that of brain uptake (0.75 *vs* 0.54; *P* = 0.025). The optimal cut-off values of brain uptake and whole-body uptake for detecting IPVD were 5.7% and 42.5%, respectively. The sensitivity, specificity, and accuracy of brain uptake > 5.7% and whole-body uptake > 42.5% for detecting IPVD were 23%, 89%, and 59% and 100%, 52%, and 74%, respectively.

***Research conclusions***

Whole-body uptake is superior to brain uptake for diagnosing HPS.

***Research perspectives***

Whole-body uptake is superior to brain uptake for diagnosing HPS. Further studies are needed to confirm the findings of the current study. For detecting IPVD and diagnosing HPS, whole-body uptake should be considered as the standard technique for calculating the shunt fraction from macroaggregated albumin lung perfusion scan.

**REFERENCES**

1 **Machicao VI**, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. *Hepatology* 2014; **59**: 1627-1637 [PMID: 24089295 DOI: 10.1002/hep.26745]

2 **Rodríguez-Roisin R**, Krowka MJ. Hepatopulmonary syndrome--a liver-induced lung vascular disorder. *N Engl J Med* 2008; **358**: 2378-2387 [PMID: 18509123 DOI: 10.1056/NEJMra0707185]

3 **Schenk P**, Fuhrmann V, Madl C, Funk G, Lehr S, Kandel O, Müller C. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. *Gut* 2002; **51**: 853-859 [PMID: 12427789 DOI: 10.1136/gut.51.6.853]

4 **Krowka MJ**, Wiesner RH, Heimbach JK. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. *J Hepatol* 2013; **59**: 367-374 [PMID: 23557870 DOI: 10.1016/j.jhep.2013.03.026]

5 **Raevens S**, Geerts A, Van Steenkiste C, Verhelst X, Van Vlierberghe H, Colle I. Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. *Liver Int* 2015; **35**: 1646-1660 [PMID: 25627425 DOI: 10.1111/liv.12791]

6 **Abrams GA**, Jaffe CC, Hoffer PB, Binder HJ, Fallon MB. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. *Gastroenterology* 1995; **109**: 1283-1288 [PMID: 7557096 DOI: 10.1016/0016-5085(95)90589-8]

7 **Abrams GA**, Nanda NC, Dubovsky EV, Krowka MJ, Fallon MB. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. *Gastroenterology* 1998; **114**: 305-310 [PMID: 9453490 DOI: 10.1016/s0016-5085(98)70481-0]

8 **Krowka MJ**, Wiseman GA, Burnett OL, Spivey JR, Therneau T, Porayko MK, Wiesner RH. Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)Tc MAA lung scanning. *Chest* 2000; **118**: 615-624 [PMID: 10988181 DOI: 10.1378/chest.118.3.615]

9 **Arguedas MR**, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. *Hepatology* 2003; **37**: 192-197 [PMID: 12500204 DOI: 10.1053/jhep.2003.50023]

10 **Surasi DS**, Manapragada P, Bhambhvani P. Lung perfusion imaging in hepatopulmonary syndrome using (99m)Tc macroaggregated albumin. *J Nucl Cardiol* 2015; **22**: 586-588 [PMID: 25164140 DOI: 10.1007/s12350-014-9990-5]

11 **Vedrinne JM**, Duperret S, Bizollon T, Magnin C, Motin J, Trepo C, Ducerf C. Comparison of transesophageal and transthoracic contrast echocardiography for detection of an intrapulmonary shunt in liver disease. *Chest* 1997; **111**: 1236-1240 [PMID: 9149575 DOI: 10.1378/chest.111.5.1236]

12 **Fuhrmann V**, Madl C, Mueller C, Holzinger U, Kitzberger R, Funk GC, Schenk P. Hepatopulmonary syndrome in patients with hypoxic hepatitis. *Gastroenterology* 2006; **131**: 69-75 [PMID: 16831591 DOI: 10.1053/j.gastro.2006.04.014]

13 **Gates GF**, Orme HW, Dore EK. Cardiac shunt assessment in children with macroaggregated albumin technetium-99m. *Radiology* 1974; **112**: 649-653 [PMID: 4843299 DOI: 10.1148/112.3.649]

14 **MacDonald A**, Burrell S. Infrequently performed studies in nuclear medicine: Part 1. *J Nucl Med Technol* 2008; **36**: 132-43; quiz 145 [PMID: 18703616 DOI: 10.2967/jnmt.108.051383]

15 **Wade L,** Bishop JM. Cardiac output and regional blood flow. Blackwell Scientific Publications 1962: 86-89

16 **Guevara M**, Bru C, Ginès P, Fernández-Esparrach G, Sort P, Bataller R, Jiménez W, Arroyo V, Rodés. Increased cerebrovascular resistance in cirrhotic patients with ascites. *Hepatology* 1998; **28**: 39-44 [PMID: 9657094 DOI: 10.1002/hep.510280107]

17 **Kalambokis G**, Tsianos EV. Pitfalls in the assessment of intrapulmonary shunt using lung perfusion scintigraphy in patients with cirrhosis. *Liver Int* 2011; **31**: 138-9; author reply 139-40 [PMID: 21129146 DOI: 10.1111/j.1478-3231.2010.02330.x]

18 **Zhao H**, Tsauo J, Zhang X, Ma H, Weng N, Wang L, Li X. Pulmonary transit time derived from pulmonary angiography for the diagnosis of hepatopulmonary syndrome. *Liver Int* 2018; **38**: 1974-1981 [PMID: 29573542 DOI: 10.1111/liv.13741]

19 **Rodríguez-Roisin R**, Krowka MJ, Hervé P, Fallon MB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). *Eur Respir J* 2004; **24**: 861-880 [PMID: 15516683 DOI: 10.1183/09031936.04.00010904]

20 **Kalambokis G**, Baltayiannis G, Tsiouris S, Pappas K, Kokkinou P, Fotopoulos A, Tsianos EV. Scintigraphic evaluation of intrapulmonary shunt in normoxemic cirrhotic patients and effects of terlipressin. *Hepatol Res* 2010; **40**: 1015-1021 [PMID: 20887337 DOI: 10.1111/j.1872-034X.2010.00715.x]

21 **Faraci FM**. Effects of endothelin and vasopressin on cerebral blood vessels. *Am J Physiol* 1989; **257**: H799-H803 [PMID: 2675632 DOI: 10.1152/ajpheart.1989.257.3.H799]

22 **Wolfe JD**, Tashkin DP, Holly FE, Brachman MB, Genovesi MG. Hypoxemia of cirrhosis: detection of abnormal small pulmonary vascular channels by a quantitative radionuclide method. *Am J Med* 1977; **63**: 746-754 [PMID: 930949 DOI: 10.1016/0002-9343(77)90161-9]

23 **Zhao H**, Tsauo J, Ma HY, Li X. The role of macroaggregated albumin lung perfusion scan in hepatopulmonary syndrome: are we ready to draw conclusions? *Liver Int* 2015; **35**: 1918-1919 [PMID: 25688443 DOI: 10.1111/liv.12810]

**Footnotes**

**Institutional review board statement:** This prospective study was approved by the institutional review board of West China Hospital (Identifier, 2014-234).

**Informed consent statement:** All study participants, or their legal guardian, provided written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**Data sharing statement:** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**CONSORT 2010 statement:** The guidelines of the CONSORT 2010 Statement have been adopted.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding Author's Membership in Professional Societies:** Chinese Society of Interventional Radiology (Vice President).

**Peer-review started:** November 14, 2019

**First decision:** December 30, 2019

**Article in press:** January 19, 2020

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Auzinger G **S-Editor:** Zhang L **L-Editor:** Filipodia **E-Editor:** Zhang YL

**Figure Legends**



**Figure 1** **Flowchart of patient selection.**



**Figure 2 Macroaggregated albumin** **lung perfusion scan in a 47-year-old female with very severe hepatopulmonary syndrome.** A: The brain uptake was 35%; B: The whole-body uptake was 58%.



**Figure 3 Receiver operating characteristic curves of brain and whole-body uptake for detecting** **intrapulmonary vascular dilatations.**

**Table 1 Demographics and clinical characteristics of patients with and those without intrapulmonary vascular dilatations**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All patients, *n* = 69** | **IPVD, *n* = 32** | **Non-IPVD, *n* = 37** | ***P* value** |
| Age in yr | 53.6 ± 12.2 | 54.1 ± 11.6 | 53.1 ± 12.8 | 0.739 |
| Sex, male/female | 46/23 (67/33) | 21/11 (66/34) | 25/12 (68/32) | 0.864 |
| Etiology |  |  |  | 0.460 |
| Hepatitis B virus infection  | 16 (23) | 7 (22) | 9 (24) |  |
| Budd-Chiari syndrome | 15 (22) | 6 (19) | 9 (24) |  |
| Hepatocellular carcinoma | 15 (22) | 9 (28) | 6 (16) |  |
| Alcoholic liver disease  | 10 (14) | 5 (16) | 5 (14) |  |
| Cryptogenic | 4 (6) | 3 (9) | 1 (3) |  |
| Others | 9 (13) | 2 (6) | 7 (19) |  |
| Child-Pugh class, A/B/C | 31/32/6 (45/46/9) | 11/18/3 (34/56/10) | 20/14/3 (54/38/8) | 0.262 |
| Child-Pugh score | 7.0 ± 1.6 | 7.2 ± 1.6 | 6.9 ± 1.6 | 0.457 |
| MELD score | 9.8 ± 2.9 | 9.8 ± 2.5 | 9.7 ± 3.2 | 0.913 |
| Bilirubin in mg/dL | 1.5 ± 0.8 | 1.7 ± 1.0 | 1.3 ± 0.5 | 0.198 |
| Albumin in g/L | 35.4 ± 5.2 | 35.2 ± 5.5 | 35.6 ± 5.1 | 0.720 |
| Creatinine in mg/dL | 0.77 ± 0.22 | 0.71 ± 0.18 | 0.83 ± 0.23 | 0.041 |
| International normalized ratio | 1.26 ± 0.18 | 1.26 ± 0.15 | 1.26 ± 0.20 | 0.963 |
| Variceal bleeding | 38 (55) | 17 (45) | 21 (55) | 0.762 |
| Ascites | 37 (54) | 19 (51) | 18 (49) | 0.373 |
| FEV1/FVC, % predicted | 85.3 ± 6.8 | 84.4 ± 6.2 | 86.2 ± 7.5 | 0.553 |
| Arterial blood gas |
| PaO2 in mmHg | 85.8 ± 13.2 | 81.0 ± 12.1 | 90.1 ± 12.8 | 0.004 |
| PaCO2 in mmHg | 35.7 ± 5.1 | 36.5 ± 4.5 | 35.1 ± 5.6 | 0.255 |
| AaO2 in mmHg | 19.6 ± 14.0 | 23.2 ± 13.3 | 16.4 ± 14.1 | 0.043 |
| MAA shunt fractions derived from different formulas |
| Brain-lung uptake | 4.4 ± 4.3 | 5.3 ± 6.0 | 3.6 ± 1.8 | 0.245 |
| Whole-body uptake | 43.8 ± 8.2 | 48.0 ± 6.1 | 40.1 ± 8.1 | 0.001 |

Data are presented as means ± SD or as numbers of patients (percentiles). IPVD: Intrapulmonary vascular dilatations; MELD: Model for end-stage liver disease; FEV1: Forced expiratory volume in 1 second; FVC: Forced vital capacity; PaO2: Partial arterial pressure of oxygen; PaCO2: Partial arterial pressure of carbon dioxide; AaO2: Alveolar-arterial oxygen gradient.

**Table 2 Demographics and clinical characteristics of patients who underwent** **acquisition of local images followed by whole-body images and *vice versa***

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Local images followed by whole-body images, *n* = 33** | **Whole-body images followed by local images, *n* = 36** | ***P* value** |
| Age in yr | 52.8 ± 12.0 | 54.4 ± 12.5 | 0.588 |
| Sex, male/female | 20/13 (61/39) | 26/10 (72/28) | 0.307 |
| Etiology |  |  | 0.161 |
| Hepatitis B virus infection | 12 (36) | 4 (11) |  |
| Budd-Chiari syndrome | 7 (21) | 8 (22) |  |
| Hepatocellular carcinoma | 4 (12) | 11 (31) |  |
| Alcoholic liver disease | 4 (12) | 6 (17) |  |
| Cryptogenic | 2 (6) | 2 (6) |  |
| Others | 4 (12) | 5 (14) |  |
| Child-Pugh class, A/B/C | 16/16/1 (48/48/3) | 15/16/5 (42/44/14) | 0.344 |
| Child-Pugh score | 6.9 ± 1.5 | 7.1 ± 1.7 | 0.458 |
| MELD score  | 9.4 ± 2.4 | 10.0 ± 3.2 | 0.436 |
| Bilirubin in mg/dL | 1.5 ± 0.9 | 1.5 ± 0.7 | 0.958 |
| Albumin in g/L | 35.0 ± 5.0 | 35.8 ± 5.5 | 0.510 |
| Creatinine in mg/dL | 0.76 ± 0.21 | 0.78 ± 0.23 | 0.757 |
| International normalized ratio | 1.24 ± 0.14 | 1.28 ± 0.20 | 0.298 |
| Variceal bleeding | 22 (58) | 16 (42) | 0.064 |
| Ascites | 16 (43) | 21 (57) | 0.413 |
| FEV1/FVC, % predicted | 86.3 ± 7.5 | 84.3 ± 6.2 | 0.524 |
| Arterial blood gas |
| PaO2 in mmHg) | 87.6 ± 10.0 | 84.2 ± 15.6 | 0.283 |
| PaCO2 in mmHg | 35.9 ± 5.1 | 35.6 ± 5.2 | 0.785 |
| AaO2 in mmHg | 17.5 ± 11.4 | 21.6 ± 16.0 | 0.225 |
| IPVD | 13 (41) | 19 (59) | 0.265 |
| HPS | 12 (46) | 14 (54) | 0.829 |
| Brain-lung uptake | 3.5 ± 1.7 | 5.3 ± 5.6 | 0.158 |
| Whole-body uptake | 42.7 ± 10.0 | 44.7 ± 6.5 | 0.393 |

Data are presented as means ± SD or as numbers of patients (percentiles). MAA: Technetium-99m-labeled macroaggregated albumin; MELD: Model for end-stage liver disease; FEV1: Forced expiratory volume in 1 second; FVC: Forced vital capacity; PaO2: Partial arterial pressure of oxygen; PaCO2: Partial arterial pressure of carbon dioxide; AaO2: Alveolar-arterial oxygen gradient; IPVD: Intrapulmonary vascular dilatations; HPS: Hepatopulmonary syndrome.

**Table 3 Multivariable logistic regression analysis of intrapulmonary vascular dilatations**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **β coefficients** | **SE** | ***P* value** | **OR** | **95%CI** |
| Age | 0.008 | 0.028 | 0.768 | 1.008 | 0.954–1.066 |
| Sex | 0.372 | 0.938 | 0.692 | 1.450 | 0.230–9.122 |
| Creatinine | -2.350 | 2.257 | 0.298 | 0.095 | 0.001–7.949 |
| Whole-body uptake | 0.254 | 0.095 | 0.008 | 1.289 | 1.069–1.554 |

IPVD: Intrapulmonary vascular dilatations; SE: Standard error; OR: Odds ratio; CI: Confidence interval.

**Table 4** **Utility of macroaggregated albumin lung perfusion scan for detecting intrapulmonary vascular dilatations**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Sensitivity, %** | **Specificity, %** | **PPV, %** | **NPV, %** | **Accuracy, %** |
| CEE | 100 | 86 | 81 | 100 | 91 |
| Brain-lung uptake > 6% | 19 | 92 | 67 | 58 | 59 |
| Brain-lung uptake > 5.7% | 23 | 89 | 64 | 58 | 59 |
| Whole-body uptake > 42.5% | 100 | 52 | 65 | 100 | 74 |
|  |

MAA: Technetium-99m-labeled macroaggregated albumin; IPVD: Intrapulmonary vascular dilatations; CEE: Contrast-enhanced echocardiography; PPV: Positive predictive value; NPV: Negative predictive value.